S
Stewart Goldman
Researcher at Children's Memorial Hospital
Publications - 57
Citations - 3249
Stewart Goldman is an academic researcher from Children's Memorial Hospital. The author has contributed to research in topics: Glioma & Medulloblastoma. The author has an hindex of 28, co-authored 57 publications receiving 2421 citations. Previous affiliations of Stewart Goldman include University of Louisville & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma
Adam M. Fontebasso,Simon Papillon-Cavanagh,Jeremy Schwartzentruber,Hamid Nikbakht,Noha Gerges,Pierre Fiset,Denise Bechet,Damien Faury,Nicolas De Jay,Lori A. Ramkissoon,Aoife Corcoran,David T.W. Jones,Dominik Sturm,Pascal Johann,Tadanori Tomita,Stewart Goldman,Mahmoud Nagib,Anne Bendel,Liliana Goumnerova,Daniel C. Bowers,Jeffrey R. Leonard,Joshua B. Rubin,Tord D. Alden,Samuel R. Browd,J. Russell Geyer,Sarah Leary,George I. Jallo,Kenneth J. Cohen,Nalin Gupta,Michael D. Prados,Anne Sophie Carret,Benjamin Ellezam,Louis Crevier,Almos Klekner,László Bognár,Peter Hauser,Miklós Garami,John S. Myseros,Zhifeng Dong,Peter M. Siegel,Hayley Malkin,Azra H. Ligon,Steffen Albrecht,Stefan M. Pfister,Keith L. Ligon,Jacek Majewski,Nada Jabado,Mark W. Kieran +47 more
TL;DR: Global DNA methylation profiles were significantly associated with the p.Lys27Met alteration, regardless of the mutant histone H3 variant and irrespective of tumor location, supporting the role of this substitution in driving the epigenetic phenotype.
Journal ArticleDOI
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson,Brent A. Orr,Gang Wu,Sridharan Gururangan,Tong Lin,Ibrahim Qaddoumi,Roger J. Packer,Stewart Goldman,Michael D. Prados,Annick Desjardins,Murali Chintagumpala,Naoko Takebe,Sue C. Kaste,Michael Rusch,Sariah Allen,Arzu Onar-Thomas,Clinton F. Stewart,Maryam Fouladi,James M. Boyett,Richard J. Gilbertson,Tom Curran,David W. Ellison,Amar Gajjar +22 more
TL;DR: Molecular analyses support the hypothesis that SMO inhibitor activity depends on the genomic aberrations within the tumor and should be advanced in SHH-MB studies.
Journal ArticleDOI
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee,Regina I. Jakacki,Arzu Onar-Thomas,Shengjie Wu,Theodore Nicolaides,Tina Young Poussaint,Jason Fangusaro,Joanna J. Phillips,Arie Perry,David C. Turner,Michael D. Prados,Roger J. Packer,Ibrahim Qaddoumi,Sridharan Gururangan,Ian F. Pollack,Stewart Goldman,Lawrence A. Doyle,Clinton F. Stewart,James M. Boyett,Larry E. Kun,Maryam Fouladi +20 more
TL;DR: Selumetinib has promising antitumor activity in children with LGG and the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumet inib inChildren with progressive LGG are determined.
Journal ArticleDOI
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.
Lindsey M. Hoffman,Sophie E. M. Veldhuijzen van Zanten,Niclas Colditz,Joshua J Baugh,Brooklyn Chaney,Marion Hoffmann,Marion Hoffmann,Adam Lane,Christine Fuller,Lili Miles,Cynthia Hawkins,Ute Bartels,Eric Bouffet,Stewart Goldman,Sarah Leary,Nicholas K. Foreman,Roger J. Packer,Katherine E. Warren,Alberto Broniscer,Mark W. Kieran,Jane E. Minturn,Melanie Comito,Emmett Broxson,Chie Schin Shih,Soumen Khatua,Murali Chintagumpala,Anne Sophie Carret,Nancy Yanez Escorza,Tim Hassall,David S. Ziegler,David S. Ziegler,Nicholas G. Gottardo,Hetal Dholaria,Renee Doughman,Martin Benesch,Rachid Drissi,Javad Nazarian,Nada Jabado,Nathalie Boddaert,Pascale Varlet,Géraldine Giraud,Géraldine Giraud,David Castel,Stéphanie Puget,Chris Jones,Esther Hulleman,Piergiorgio Modena,Marzia Giagnacovo,Manila Antonelli,Torsten Pietsch,Gerrit H. Gielen,David T.W. Jones,Dominik Sturm,Dominik Sturm,Stefan M. Pfister,Stefan M. Pfister,Nicolas U. Gerber,Michael A. Grotzer,Elke Pfaff,Elke Pfaff,André O. von Bueren,Darren Hargrave,Guirish A. Solanki,Filip Jadrijevic Cvrlje,Gertjan J.L. Kaspers,Gertjan J.L. Kaspers,William P. Vandertop,Jacques Grill,Simon Bailey,Veronica Biassoni,Maura Massimino,Raphael Calmon,Esther Sanchez,Brigitte Bison,Monika Warmuth-Metz,James L. Leach,Blaise V. Jones,Dannis G. van Vuurden,Christof M. Kramm,Maryam Fouladi +79 more
TL;DR: Clinical, radiologic, and molecular factors that correlate with survival in children and young adults with DIPG are reported, which are important for risk stratification in future clinical trials.
Journal ArticleDOI
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis
Vijay Ramaswamy,Thomas Hielscher,Stephen C. Mack,Stephen C. Mack,Alvaro Lassaletta,Tong Lin,Kristian W. Pajtler,David T.W. Jones,Betty Luu,Florence M.G. Cavalli,Kenneth Aldape,Marc Remke,Martin Mynarek,Stefan Rutkowski,Sridharan Gururangan,Roger E. McLendon,Eric S. Lipp,Christopher Dunham,Juliette Hukin,David D. Eisenstat,Dorcas Fulton,Frank van Landeghem,Mariarita Santi,Marie Lise C. van Veelen,Erwin G. Van Meir,Satoru Osuka,Xing Fan,Karin M. Muraszko,Daniela Pretti da Cunha Tirapelli,Sueli Mieko Oba-Shinjo,Suely Kazue Nagahashi Marie,Carlos Gilberto Carlotti,Ji Yeoun Lee,Amulya A. Nageswara Rao,Caterina Giannini,Claudia C. Faria,Sofia Nunes,Jaume Mora,Ronald L. Hamilton,Peter Hauser,Nada Jabado,Kevin Petrecca,Shin Jung,Luca Massimi,Massimo Zollo,Giuseppe Cinalli,László Bognár,Almos Klekner,Tibor Hortobágyi,Sarah Leary,Sarah Leary,Sarah Leary,Ralph P. Ermoian,Ralph P. Ermoian,Ralph P. Ermoian,James M. Olson,James M. Olson,James M. Olson,Jeffrey R. Leonard,Corrine Gardner,Wiesława Grajkowska,Lola B. Chambless,Jason E. Cain,Charles G. Eberhart,Sama Ahsan,Maura Massimino,Felice Giangaspero,Francesca R. Buttarelli,Roger J. Packer,Lyndsey Emery,William H. Yong,Horacio Soto,Linda M. Liau,Richard Everson,Andrew J. Grossbach,Tarek Shalaby,Michael A. Grotzer,Matthias A. Karajannis,David Zagzag,Helen Wheeler,Katja von Hoff,Marta M. Alonso,Teresa Tuñón,Ulrich Schüller,Karel Zitterbart,Jaroslav Sterba,Jennifer A. Chan,Miguel A. Guzman,Samer K. Elbabaa,Howard Colman,Girish Dhall,Paul G. Fisher,Maryam Fouladi,Amar Gajjar,Stewart Goldman,Eugene Hwang,Marcel Kool,Harshad Ladha,Elizabeth Vera-Bolanos,Khalida Wani,Frank S. Lieberman,Tom Mikkelsen,Antonio Omuro,Ian F. Pollack,Michael D. Prados,H. Ian Robins,Riccardo Soffietti,Jing Wu,Phillipe Metellus,Uri Tabori,Ute Bartels,Eric Bouffet,Cynthia Hawkins,James T. Rutka,Peter B. Dirks,Stefan M. Pfister,Stefan M. Pfister,Thomas E. Merchant,Mark R. Gilbert,Mark R. Gilbert,Terri S. Armstrong,Andrey Korshunov,David W. Ellison,Michael D. Taylor +123 more
TL;DR: The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation, independent of other demographic or treatment variables, with the survival rates being particularly poor for subtotally resected EPN_PFA, even with adjuvant radiation therapy.